Itzykson et al developed a prognostic score for patients with chronic myelomonocytic leukemia (CMML). These can help to identify a patient who may benefit from more aggressive or novel therapy. The authors are from multiple institutions in France, Germany and England.
Patient selection: CMML
Parameters:
(1) age in years
(2) hemoglobin and gender (anemia)
(3) WBC count
(4) platelet count
(5) ASXL1 mutation
|
Parameter |
Finding |
Points |
|
age in years |
<= 65 years of age |
0 |
|
|
> 65 years of age |
2 |
|
hemoglobin and gender |
male and hemoglobin < 11 g/dL |
2 |
|
|
female and hemoglobin < 10 g/dL |
2 |
|
|
other |
0 |
|
WBC count |
<= 150,000 per µL |
0 |
|
|
> 150,000 per µL |
3 |
|
platelet count |
>= 100,000 per µL |
0 |
|
|
< 100,000 per µL |
2 |
|
ASXL1 mutation |
no |
0 |
|
|
yes |
2 |
total score =
= SUM(points for all 5 parameters)
Interpretation:
• minimum score: 0
• maximum score: 11
• The higher the score the worse the prognosis.
|
Total Score |
Risk Group |
Median Overall Survival |
|
0 to 4 |
low |
59 months |
|
5 to 7 |
intermediate |
30 months |
|
8 to 11 |
high |
17 months |
Specialty: Hematology Oncology, Clinical Laboratory
ICD-10: ,
